Fig. 2: Impact of transplantation group vs. chemotherapy group on clinical outcomes in KMT2A-r AML after CR1. | Blood Cancer Journal

Fig. 2: Impact of transplantation group vs. chemotherapy group on clinical outcomes in KMT2A-r AML after CR1.

From: Outcomes of acute myeloid leukemia with KMT2A (MLL) rearrangement: a multicenter study of TROPHY group

Fig. 2

The OS (A) and CIR (B) of patients who underwent allo-HSCT at CR1 compared to those who received chemotherapy only. The OS (C) and CIR (D) of patients with KMT2A::MLLT3 who underwent allo-HSCT at CR1 compared to those who received chemotherapy only. The transplantation group included patients who underwent allo-HSCT in CR1. The chemotherapy group included patients who received chemotherapy only in CR1. OS overall survival, CIR cumulative incidence of relapse, Allo-HSCT allogeneic hematopoietic stem cell transplantation, AML acute myeloid leukemia, CR1 first complete remission. Note: The 6th month after diagnosis was chosen as the landmark time. The curve does not show the censored points; the censored data are shown at the bottom along with the risk table.

Back to article page